Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET
Company Participants
Joshua Higa – VP, IR
Emil Kakkis – CEO and President
Erik Harris – CCO
Howard Horn – CFO
Eric Crombez – CMO
Conference Call Participants
Tazeen Ahmad – Bank of America
Salveen Richter – Goldman Sachs
Gena Wang – Barclays
Yaron Werber – TD Cowen
Joon Lee – Truist Securities
Jeff Hung – Morgan Stanley
Rick Miller – Cantor Fitzgerald
Luca Isssi – RBC Capital
Liisa Bayko – Evercore isi
Operator
Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A portion of the call.
It is now my pleasure to turn over the call to Joshua Higa, Vice President of Investor Relations. Please go ahead.
Joshua Higa
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.
I’d like to remind everyone that during today’s call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I’ll now turn the call over to Emil.
Emil Kakkis
Thanks, Josh, and good afternoon, everyone. 2024 was a pivotal year for the company as we advanced 6 late-stage programs in serious genetic conditions, most without any approved therapies, while also expanding access and growing revenue from our four commercial products worldwide.
GIPHY App Key not set. Please check settings